Cornell Study Warns Recent Federal Shift in Newborn Hepatitis B Vaccination Could Cost $370 Million in Healthcare Expenses

New Cornell University research warns that delaying the hepatitis B birth dose will increase newborn infections and create $370 million in medical costs.

By: AXL Media

Published: Apr 28, 2026, 6:07 AM EDT

Source: Information for this report was sourced from EurekAlert

The Financial and Clinical Risks of Immunization Delays

A comprehensive study from Cornell University has quantified the potential human and economic toll of a recent shift in national pediatric vaccination policy. Researchers discovered that moving the first dose of the hepatitis B vaccine away from the 24-hour birth window directly correlates with higher infection rates and lower quality of life for newborns. The study, published in JAMA Pediatrics, utilized probabilistic models to estimate that these delays could incur healthcare costs ranging from $16 million to $370 million. According to Noele Nelson, a professor at Cornell and the study’s senior author, any delay in the first dose represents a significant setback for national efforts to eliminate the virus.

Challenging the Federal Reversal of Universal Birth Doses

The research arrives as a direct response to a December 2025 decision by the federal Advisory Committee on Immunization Practices (ACIP). The committee voted to reverse a 2018 recommendation that mandated the vaccine for all infants within 24 hours of birth, instead allowing delays for infants whose birth parents test negative for the virus. The Cornell team argues that this policy change rests on a precarious assumption about maternal screening accuracy. Their modeling suggests that in unvaccinated groups, a higher number of individuals will inevitably progress to chronic infection, cirrhosis, and liver cancer, particularly if they fail to complete the subsequent three-dose series.

The High Vulnerability of Neonatal Populations

Newborns represent the highest-risk group for long-term complications from hepatitis B, with 90% of those who contract the virus developing chronic, lifelong infections. Furthermore, roughly 25% of these infants will eventually die prematurely from liver-related failures or cancer. The Cornell study highlights that the low incidence of the virus in the United States, which the ACIP cited as a reason for the policy shift, is actually a direct result of the successful 2018 universal birth-dose mandate. By removing this safeguard, policymakers may be dismantling the very mechanism that achieved the current low-risk environment.